<DOC>
	<DOCNO>NCT00403104</DOCNO>
	<brief_summary>The purpose study determine oral treatment ONO-2506PO patient diagnosed ALS , onset muscle weakness within 14 month randomization , could lead slow decline respiratory function , functional status , muscle strength , quality life survival compare placebo group .</brief_summary>
	<brief_title>Placebo Controlled Study ONO2506PO Presence Riluzole Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>1 . Diagnosis clinically possible , clinically probable laboratorysupported , clinically probable clinically definite ALS ( accord WNF EL Escorial diagnostic criterion , revise accord Airlie House Conference 1998 ) 2 . Onset muscle weakness within 14 month randomization 3 . Concomitant standard Riluzole therapy ( 50mg twice daily ) 1 . Presence tracheotomy , mechanical ventilation noninvasive ventilation 2 . Requirement prescription drug use potential neuroprotective benefit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-2506PO</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>ALS</keyword>
</DOC>